Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 (GLP)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2007 by Assaf-Harofeh Medical Center.
Recruitment status was  Not yet recruiting
Information provided by:
Assaf-Harofeh Medical Center Identifier:
First received: May 13, 2007
Last updated: May 14, 2007
Last verified: April 2007

Glucagon like peptides receptors expression in the stomach of diabetes type 2 Glucagon like peptides (GLP-1, GLP-2), are hormones secreted by L cells located along the gastrointestinal tract. These hormones are secreted after meals and have some roles in regulating the digestion process, absorption, and sending signals to the brain that regulate food consumption. GLP peptides affect peripheral targets and have an important homeostatic role. GLP-1 decreases the circulatory glucose level and GLP-2 has trophic effects which enable adequate intestine growth.

We aimed in our study to investigate the GLP-1 and GLP-2 receptor expression in different zones of the stomach in diabetes type 2 patients. If there are differences, it might explain the pathological gastric emptying in these patients.

Understanding the function of these peptides may lead to new therapeutic options for diabetic patients with delayed gastric emptying.

Methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years. Patients with neurological disease will be excluded. During esophagogastroduodenoscopy 3 biopsies will be taken from the antrum, corpus and cardia. The biopsies will be stored in -70. After RNA extraction the GLP receptors expression will established by real time PCR method. Patients with different expression compared to control will undergo isotopic scan for gastric emptying.

Condition Intervention Phase
Diabetes Mellitus Type 2
Procedure: GLP receptors expression
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Diagnostic

Resource links provided by NLM:

Further study details as provided by Assaf-Harofeh Medical Center:


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years

Exclusion Criteria:

  • Patients with neurological disease will be excluded
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00473733

Contact: Efrat Broide, MD 972-8-9779722

Assaf Harofeh Medical Center Not yet recruiting
Zerifin, Israel, 70300
Contact: eFRAT Broide, MD    972-8-9779722   
Principal Investigator: Efrat Broide, MD         
Sponsors and Collaborators
Assaf-Harofeh Medical Center
Principal Investigator: Efrat Broide, MD Ethic committee of Asaaf Harofeh Medical Center
  More Information

No publications provided Identifier: NCT00473733     History of Changes
Other Study ID Numbers: 65/07
Study First Received: May 13, 2007
Last Updated: May 14, 2007
Health Authority: Israel: "Ethic committee of Assaf Harofeh Medical Center"

Keywords provided by Assaf-Harofeh Medical Center:

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases processed this record on December 01, 2015